(AKE) Arkema - Overview
Stock: Adhesives, Acrylics, Polyamides, PVDF, Resins
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.67% |
| Yield on Cost 5y | 4.86% |
| Yield CAGR 5y | 9.54% |
| Payout Consistency | 97.3% |
| Payout Ratio | 92.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Relative Tail Risk | -4.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.72 |
| Alpha | -31.24 |
| Character TTM | |
|---|---|
| Beta | 0.377 |
| Beta Downside | 0.579 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.40% |
| CAGR/Max DD | -0.24 |
Description: AKE Arkema January 08, 2026
Arkema S.A. (NYSE: AKE) is a French-based diversified chemicals producer that sells specialty materials across Europe, North America, and Asia. It operates three business segments: Adhesive Solutions (building, automotive, packaging, and performance polymers), Advanced Materials & Coating Solutions (coatings, additives, 3D-printing and electronics chemistries), and Intermediates (fluorogases, acrylics, and other industrial chemicals). The company’s portfolio focuses on high-value, performance-driven chemistries used in construction, transportation, and water-treatment markets.
Key recent metrics: 2023 revenue reached €9.3 billion with an adjusted EBITDA margin of roughly 13 %, and capex was about €500 million, reflecting continued investment in specialty polymer capacity. Growth is being driven by (1) the global push for lightweighting in EVs and aerospace, boosting demand for polyamides and fluoropolymers; (2) stricter EU regulations on high-global-warming-potential fluorogases, prompting Arkema’s shift toward low-GWP alternatives; and (3) a resurgence in construction and renovation activity in Europe and North America, which lifts adhesive and coating volumes. Base-rate analysis suggests that companies with >10 % exposure to high-margin specialty polymers have historically outperformed the broader chemicals index by 2–3 % annualized over the past five years.
For a deeper, data-rich assessment of Arkema’s valuation and risk profile, you may find the ValueRay platform’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 143.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.82 > 1.0 |
| NWC/Revenue: 36.00% < 20% (prev 28.51%; Δ 7.50% < -1%) |
| CFO/TA 0.07 > 3% & CFO 980.0m > Net Income 143.0m |
| Net Debt (-1.95b) to EBITDA (1.00b): -1.95 < 3 |
| Current Ratio: 3.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (76.1m) vs 12m ago -7.79% < -2% |
| Gross Margin: 18.68% > 18% (prev 0.20%; Δ 1847 % > 0.5%) |
| Asset Turnover: 63.80% > 50% (prev 64.77%; Δ -0.97% > 0%) |
| Interest Coverage Ratio: 1.87 > 6 (EBITDA TTM 1.00b / Interest Expense TTM 111.0m) |
Altman Z'' 3.44
| A: 0.23 (Total Current Assets 4.93b - Total Current Liabilities 1.60b) / Total Assets 14.30b |
| B: 0.31 (Retained Earnings 4.48b / Total Assets 14.30b) |
| C: 0.01 (EBIT TTM 208.0m / Avg Total Assets 14.48b) |
| D: 0.76 (Book Value of Equity 5.24b / Total Liabilities 6.88b) |
| Altman-Z'' Score: 3.44 = A |
Beneish M -3.05
| DSRI: 0.98 (Receivables 1.54b/1.61b, Revenue 9.24b/9.49b) |
| GMI: 1.09 (GM 18.68% / 20.45%) |
| AQI: 0.98 (AQ_t 0.39 / AQ_t-1 0.39) |
| SGI: 0.97 (Revenue 9.24b / 9.49b) |
| TATA: -0.06 (NI 143.0m - CFO 980.0m) / TA 14.30b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of AKE shares?
Over the past week, the price has changed by +14.06%, over one month by +8.21%, over three months by +18.32% and over the past year by -24.69%.
Is AKE a buy, sell or hold?
What are the forecasts/targets for the AKE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.6 | 6.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 56.2 | -3.2% |
AKE Fundamental Data Overview February 03, 2026
P/E Trailing = 32.5962
P/E Forward = 12.7877
P/S = 0.4165
P/B = 0.5384
P/EG = 0.4673
Revenue TTM = 9.24b EUR
EBIT TTM = 208.0m EUR
EBITDA TTM = 1.00b EUR
Long Term Debt = 3.37b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 142.0m EUR (from shortTermDebt, last quarter)
Debt = 5.36b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.95b EUR (from netDebt column, last quarter)
Enterprise Value = 7.25b EUR (3.85b + Debt 5.36b - CCE 1.95b)
Interest Coverage Ratio = 1.87 (Ebit TTM 208.0m / Interest Expense TTM 111.0m)
EV/FCF = 29.71x (Enterprise Value 7.25b / FCF TTM 244.0m)
FCF Yield = 3.37% (FCF TTM 244.0m / Enterprise Value 7.25b)
FCF Margin = 2.64% (FCF TTM 244.0m / Revenue TTM 9.24b)
Net Margin = 1.55% (Net Income TTM 143.0m / Revenue TTM 9.24b)
Gross Margin = 18.68% ((Revenue TTM 9.24b - Cost of Revenue TTM 7.51b) / Revenue TTM)
Gross Margin QoQ = 18.56% (prev 19.00%)
Tobins Q-Ratio = 0.51 (Enterprise Value 7.25b / Total Assets 14.30b)
Interest Expense / Debt = 0.62% (Interest Expense 33.0m / Debt 5.36b)
Taxrate = 41.67% (25.0m / 60.0m)
NOPAT = 121.3m (EBIT 208.0m * (1 - 41.67%))
Current Ratio = 3.07 (Total Current Assets 4.93b / Total Current Liabilities 1.60b)
Debt / Equity = 0.74 (Debt 5.36b / totalStockholderEquity, last quarter 7.22b)
Debt / EBITDA = -1.95 (Net Debt -1.95b / EBITDA 1.00b)
Debt / FCF = -8.00 (Net Debt -1.95b / FCF TTM 244.0m)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.99% (Net Income 143.0m / Total Assets 14.30b)
RoE = 1.95% (Net Income TTM 143.0m / Total Stockholder Equity 7.34b)
RoCE = 1.94% (EBIT 208.0m / Capital Employed (Equity 7.34b + L.T.Debt 3.37b))
RoIC = 1.31% (NOPAT 121.3m / Invested Capital 9.24b)
WACC = 3.27% (E(3.85b)/V(9.20b) * Re(7.32%) + D(5.36b)/V(9.20b) * Rd(0.62%) * (1-Tc(0.42)))
Discount Rate = 7.32% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.22%
[DCF Debug] Terminal Value 84.54% ; FCFF base≈353.2m ; Y1≈300.3m ; Y5≈229.8m
Fair Price DCF = 118.4 (EV 7.00b - Net Debt -1.95b = Equity 8.95b / Shares 75.6m; r=5.90% [WACC]; 5y FCF grow -18.17% → 2.90% )
EPS Correlation: -63.34 | EPS CAGR: -23.57% | SUE: -0.65 | # QB: 0
Revenue Correlation: -70.08 | Revenue CAGR: -3.50% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.98 | Chg30d=-0.185 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.22 | Chg30d=-0.387 | Revisions Net=-6 | Growth EPS=+12.2% | Growth Revenue=+0.7%